Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.

Health technology assessment (Winchester, England)

Volumn 14, Issue Suppl. 2, 2010, Pages 47-53

  Whyte, S ^a   Pandor, A ^b   Stevenson, M ^b   Rees, A ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BEVACIZUMAB; FLUOROURACIL; MONOCLONAL ANTIBODY;

ADULT; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; MULTICENTER STUDY (TOPIC); PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED KINGDOM;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; ENGLAND; FLUOROURACIL; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WALES;

EID: 84886943081     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta14suppl2/07     Document Type: Review

References (0)